SCHEMBL25403246

SCHEMBL25403246

O=Cc1oc2ccccc2c1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 5/20 0.48
KDM4E B2RXH2 4/20 0.48
ALDH1A1 P00352 4/20 0.48
HPGD P15428 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
GLA P06280 1/20 0.48
CYP3A4 P08684 1/20 0.48
MAPT P10636 1/20 0.48
PGAM1 P18669 1/20 0.48
CASP1 P29466 1/20 0.48
CASP7 P55210 1/20 0.48
HSD17B10 Q99714 1/20 0.48
THRB P10828 1/20 0.43
NPC1 O15118 2/20 0.42
LMNA P02545 1/20 0.42
OPRD1 P41143 1/20 0.42
OPRK1 P41145 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
PTPN1 P18031 1/20 0.38
MAOB P27338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5794104 0.82 MAOA (0.50) MAOAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL5226658 0.78 KDM4E (0.53) MAOAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL29002071 0.76 KDM4E (0.50) MAOAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL15675913 0.76 MAOA (0.48) MAOAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL719219 0.76 L3MBTL1 (0.55) MAOAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL25405004 0.76 MAOA (0.48) MAOAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL2016355 0.76 MAOA (0.48) MAOAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL9653414 0.76 KDM4E (0.55) MAOAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL1253554 0.76 KDM4E (0.48) MAOAKDM4EALDH1A1HPGDSMN1; SMN2
SCHEMBL25405540 0.76 MAOA (0.44) MAOAKDM4EALDH1A1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250320201-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS INC (US) 2025-10-16 US disclosed
WO-2023164234-A9 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. (US) 2024-01-18 WO disclosed
WO-2023164234-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. (US) 2023-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320201-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 MAOA 425/4885KDM4E 104/4885ALDH1A1 865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.